Pharmacokinetics of an unfractionated heparin (Liquemin®) in the dog after intravenous and subcutaneous application based on heparin-activity;Pharmakokinetik des unfraktionierten heparins Liquemin® beim hund nach intravenöser und subkutaner injektion basierend auf der heparinaktivität

Deutsche Tierarztliche Wochenschrift

Volumn 106, Issue 11, 1999, Pages 478-481

  Jacobs, C ^a   Grebe, S ^a   Kietzmann, M ^a   Mischke, R ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANIMAL; ARTICLE; BLOOD; DOG; DOSE RESPONSE; HALF LIFE TIME; INFUSION; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; ANTICOAGULANTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HEPARIN; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL;

EID: 0033218473     PISSN: 03416593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. BARA, L., BILLAUD, E., GRAMOND, G., KHER, A , SAMAMA, M. (1985): Comparative pharmacokinetics of a low molecular weight heparin after intravenous and subcutaneous administration. Thromb. Res. 39, 631-636.
2. BARZU, T., MOLHO, P., TOBELEM, G., PETITOU, M., CAEN, J. (1985): Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta 845, 196-203.
3. BENDETOWICZ, A. V., BÉGUIN, S., CAPLAIN, H., HEMKER, C. (1994): Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (Enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - a three way cross over study in human volunteers. Thromb. Haemost. 71, 305-313.
4. BHARGAVA, A. S., SCHÖBEL, C., GUNZEL, P. (1981): Characterization of a new potent heparin. Arzneim.-Forsch./Drug Res. 30, 79-82.
5. BJORNSSON, T. D., LEVY, G. (1979): Pharmacokinetics of heparin I: studies of dose dependence in rats. J. Pharmacol. Exp. Ther. 210, 273-242.
6. BJORNSSON, T. O., WOLFRAM, B. S., KITCHELL, B. B. (1982): Heparin kinetics determined by three assay methods. Clin. Pharmacol. Ther. 31, 104-113.
7. BONEU, B., CARANOBE, C., GABAIG, A. M., DUPOUY, D., SIE, P., BUCHANAN, M. R., HIRSH, J. (1987): Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb. Res. 46, 835-844.
8. DAWES, J., PEPPER, D. S. (1979): Catabolism of low-dose heparin in man. Thromb. Res. 14, 845-860.
9. DE SWART, C. A. , NIJMEYER, B., ROELOFS, J. M., SIXMA, J. J. (1982): Kinetics of intravenously administered heparin in normal humans. Blood 60, 1251-1258.
10. EMANUELE, R. M., FAREED, J. (1987): The effect of molecular weight on the bioavailability of heparin. Thromb. Res. 48, 591-596.
11. ESTES, J. W., POULIN, P. P. (1974): Pharmacokinetics of heparin. Thromb. Diath. Haemorrh. 33, 26-37.
12. GENTRY, P. A. (1977): Interaction of heparin with canine coagulation proteins: in vivo and in vitro studies. Can. J. Comp. Med. 41, 396-403.
13. GLIMELIUS, B., BUSCH, C., HOOK, M. (1978): Binding of heparin on the surface of cultured human endothelial cells. Thromb. Res. 31, 773-782.
14. GREEN, R. A. (1980): Activated coagulation time in monitoring heparinized dogs. Am. J. Vet. Res. 41, 1793-1797.
15. HELLEBREKERS, L. J., SLAPPENDEL, R. J., VAN DEN BROM, W. E. (1985): Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am. J. Vet. Res. 46, 1460-1462.
16. HIRSH, J., WARKENTIN, T. E., RASCHKE, R., GRANGER, C., OHMAN, E. M., DALEN, J. E. (1998): Heparin and low-molecular-weight heparin; mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114, 489-510.
17. KANDROTAS, R. J., GAL, P., DOUGLAS, J. B., DETERDING, J. (1989): Heparin pharmacokinetics during hemodialysis. Ther. Drug Monitor. 11, 674-679.
18. KANDROTAS, R. J., GAL, P., DOUGLAS, J. B., DETERDING, J. (1990): Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. Pharmacother. 10, 349-356.
19. MAHADOO, J., HIEBERT, L., JAQUES, L. B. (1977): Vascular sequestration of heparin. Thromb. Res. 12, 773-782.
20. MCALLISTER, B. M., DEMIS, D. J. (1996): Heparin metabolism: isolation and characterization of uroheparin. Nature 212, 293-294.
21. MOMBELLI, G., SCHAEDELIN, J., BECK, E. A. (1977): Pharmakokinetik von Heparin nach einmaliger intravenöser oder subkutaner Injektion. Schweiz. Med. Wschr. 107, 810-815.
22. PERRY, M. O., HORTON, J. (1976): Kinetics of heparin administration. Arch. Surg. 111, 403-409.
23. PINI, M., PATTACHINI, C., QUINTAVALLA, R. (1990): Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis - a randomized clinical trial. Thromb. Haemost. 64, 222-226.
24. UZAN, A., MARIN, J., MARDIGUIAN, J., TRILLOU, M., KIOSSEFF, T., ROUGEOT, C. (1987): Etude pharmacocinétique comparée, chez le chien, d'une héparine de bas poids moléculaire (Enoxaparine) et de l'heparine, par marquage au soufre 35. Ann. Pharm. Fr. 45, 429-437.